DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, has completed construction on its 25,000-square-foot headquarters in Salt Lake City.
Seven things to know:
1. The company added space for a manufacturing facility in anticipation of future commercial demand for IDCT, an allogeneic, injectable disc cell therapy for degenerative disc disease, according to a Feb. 9 news release.
2. In August, DiscGenics raised $50 million in a series C funding round. It has raised more than $71 million to date.
3. Former Medtronic Spine and Biologics executive Jeff Poole serves as CFO. He speaks fluent Japanese and has lived and worked in Japan, where DiscGenics has a significant commercial interest.
4. The company recently added two new board members, including Najeeb Thomas, MD, a neurosurgeon with Southern Brain and Spine in New Orleans.
5. DiscGenics is conducting two clinical trials in the U.S. and Japan evaluating the safety and efficacy of IDCT in subjects with single-level, mild to moderate lumbar degenerative disc disease.
6. All 60 subjects have been treated in the U.S. trial, with no safety issues reported, according to the company.
7. IDCT passed the initial safety review in Japan, where enrollment is ongoing.